

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001779479
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Akero Therapeutics
SEC File Number 001-38944
Address of Issuer 601 Gateway Blvd., Suite 350
South San Francisco
CALIFORNIA
94080
Phone 650-487-6488
Name of Person for Whose Account the Securities are To Be Sold Timothy Rolph
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer Affiliate

144: Securities Information

| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | Number of Shares or Other Units Outstanding | Approximate Date of Sale | Name the Securities Exchange |
|---|--|--|------------------------|---|--------------------------|------------------------------|
| Common | J.P. Morgan Securities LLC 390 Madison Avenue - 6th Floor New York NY 10017 | 38200 | 2101000 | 50086978 | 06/16/2023 | NASDAQ |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

| Title of the Class | Date you Acquired | Nature of Acquisition | Name of Person from | Is this | Date Donor | Amount of Securities | Date of Payment | Nature of Payment * |
|--------------------|-------------------|-----------------------|---------------------|---------|------------|----------------------|-----------------|---------------------|
|--------------------|-------------------|-----------------------|---------------------|---------|------------|----------------------|-----------------|---------------------|

| | | Transaction | Whom Acquired | a Gift? | Acquired | Acquired |
|--------|------------|--|---------------|--------------------------|----------|-----------------|
| Common | 03/16/2017 | Founder stock issued by Pippin Therapeutics, Inc. pursuant to stock purchase and restriction agreement | Issuer | <input type="checkbox"/> | 467 | 03/22/2017 cash |
| Common | 03/29/2018 | Founder stock issued by Pippin Therapeutics, Inc. pursuant to stock purchase and restriction agreement | Issuer | <input type="checkbox"/> | 37733 | 04/17/2018 Cash |

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice 06/16/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Timothy Rolph

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)